Semiconductor resonant all-optical temperature sensor and thermal release trigger of encapsulated anti-cancer drugs for in vitro studies

Introduction: Vitamin D has been shown to have anti-cancer properties such as antioxidants, anti-proliferative, and cell differentiation. The property of vitamin D as an anticancer agent triggers researchers to find out whether vitamin D is useful as a radiosensitizer. Multiple studies have been carried out on cell lines in various types of cancer, but the benefits of vitamin D as a radiosensitizer still controversial. This paperwork aims to investigate the utilization of Vitamin D3 (Calcitriol) as radiosensitizer in various cell line through literature review.Methods: A systematic search of available medical literature databases was performed on in-vitro studies with Vitamin D as a radiosensitizer in all types of cell lines. A total of 11 in-vitro studies were evaluated.Results: Nine studies in this review showed a significant effect of Vitamin D as a radiosensitizer agent by promoting cytotoxic autophagy, increasing apoptosis, inhibiting of cell survival and proliferation, promoting gene in ReIB inhibition, inducing senescene and necrosis. The two remaining studies showed no significant effect in the radiosensitizing mechanism of Vitamin D due to lack of evidence in-vitro settings.Conclusion: Vitamin D have anticancer property and can be used as a radiosensitizer by imploring various mechanism pathways in various cell lines. Further research especially in-vivo settings need to be evaluated.

Download Full-text

Coherent Raman Scattering Microscopy in Oncology Pharmacokinetic Research

Frontiers in Pharmacology ◽

10.3389/fphar.2021.630167 ◽

2021 ◽

Vol 12 ◽

Author(s):

Junjie Zeng ◽

Wenying Zhao ◽

Shuhua Yue

Keyword(s):

Raman Scattering ◽

High Speed ◽

Cancer Drug ◽

Cancer Drugs ◽

High Speed Imaging ◽

Coherent Raman Scattering ◽

Anti Cancer ◽

Coherent Raman

The high attrition rates of anti-cancer drugs during clinical development remains a bottleneck problem in pharmaceutical industry. This is partially due to the lack of quantitative, selective, and rapid readouts of anti-cancer drug activity in situ with high resolution. Although fluorescence microscopy has been commonly used in oncology pharmacological research, fluorescent labels are often too large in size for small drug molecules, and thus may disturb the function or metabolism of these molecules. Such challenge can be overcome by coherent Raman scattering microscopy, which is capable of chemically selective, highly sensitive, high spatial resolution, and high-speed imaging, without the need of any labeling. Coherent Raman scattering microscopy has tremendously improved the understanding of pharmaceutical materials in the solid state, pharmacokinetics of anti-cancer drugs and nanocarriers in vitro and in vivo. This review focuses on the latest applications of coherent Raman scattering microscopy as a new emerging platform to facilitate oncology pharmacokinetic research.

Download Full-text

Haematotoxicology: Scientific Basis and Regulatory Aspects

Alternatives to Laboratory Animals ◽

10.1177/026119290203002s17 ◽

2002 ◽

Vol 30 (2_suppl) ◽

pp. 111-113 ◽

Cited By ~ 14

Author(s):

Laura Gribaldo

Keyword(s):

Target Genes ◽

Cell Types ◽

Scientific Basis ◽

Cancer Drugs ◽

Experimental Conditions ◽

Clinical Drug Development ◽

Anti Cancer ◽

Starting Dose ◽

Life Threatening

Haematopoietic tissues are the targets of numerous xenobiotics. The purpose of in vitro haematotoxicology is the prediction of adverse haematological effects from toxicants on human haematopoietic targets under controlled experimental conditions in the laboratory. Building on its foundations in experimental haematology and the wealth of haematotoxicological data found in experimental oncology, this field of alternatives toxicology has developed rapidly during the past decade. Preclinical and clinical drug development for anti-cancer drugs differs from that for other pharmaceuticals, because of the life-threatening nature of the disease. Treatment with anti-cancer drugs at clinically efficacious doses usually induces serious side-effects. The design of preclinical toxicology studies for anti-cancer drugs is intended to identify a safe clinical starting dose, characterise toxicities that could be encountered in human clinical trials, and determine whether these toxicities are reversible, manageable, and predictable. Although the myeloid colony-forming unit (CFU-GM) progenitor is most frequently evaluated, other defined progenitors and stem cells, as well as cell types found in the bone-marrow stroma, can now be evaluated in vitro. Genetic damage to haematopoietic cells can occur in the absence of any overt haematological signs. The development of tissue-specific screening systems that are able to give information about the toxic effects of chemicals, drugs and environmental hazards on target genes is needed, in order to make preliminary decisions or to set priorities for selection among large groups of chemicals and possible drugs.

Download Full-text

pH-Sensitive Ratiometric Fluorescent Probe for Evaluation of Tumor Treatments

Materials ◽

10.3390/ma12101632 ◽

2019 ◽

Vol 12 (10) ◽

pp. 1632

Author(s):

Peisen Zhang ◽

Junli Meng ◽

Yingying Li ◽

Zihua Wang ◽

Yi Hou

Keyword(s):

Ph Sensitive ◽

Fluorescent Imaging ◽

Tat Peptide ◽

Cancer Drugs ◽

Ph Response ◽

In Vivo Experiments ◽

Anti Cancer ◽

Amidation Reaction

Determining therapeutic efficacy is critical for tumor precision theranostics. In order to monitor the efficacy of anti-cancer drugs (e.g., Paclitaxel), a pH-sensitive ratiometric fluorescent imaging probe was constructed. The pH-sensitive ratiometric fluorescent dye ANNA was covalently coupled to the N-terminal of the cell-penetrating TAT peptide through an amidation reaction (TAT-ANNA). The in vitro cellular experiments determined that the TAT-ANNA probe could penetrate the cell membrane and image the intracellular pH in real time. The in vivo experiments were then carried out, and the ratiometric pH response to the state of the tumor was recorded immediately after medication. The TAT-ANNA probe was successfully used to monitor the pharmacodynamics of anti-cancer drugs in vivo.

Download Full-text

In vivo and in vitro biocompatibility study of MnFe2O4 and Cr2Fe6O12 as photosensitizer for photodynamic therapy and drug delivery of anti-cancer drugs

Drug Development and Industrial Pharmacy ◽

10.1080/03639045.2020.1757698 ◽

2020 ◽

Vol 46 (5) ◽

pp. 846-851

Author(s):

Mozhgan Aghajanzadeh ◽

Ehsan Naderi ◽

Mostafa Zamani ◽

Ali Sharafi ◽

Mahmoud Naseri ◽

...

Keyword(s):

Drug Delivery ◽

Photodynamic Therapy ◽

Cancer Drugs ◽

In Vitro Biocompatibility ◽

Anti Cancer ◽

Biocompatibility Study

Download Full-text

Therapeutic Anticancer Uses of the Active Principles of “Rhopalurus junceus” Venom

Biomedicines ◽

10.3390/biomedicines8100382 ◽

2020 ◽

Vol 8 (10) ◽

pp. 382

Author(s):

Mario Dioguardi ◽

Giorgia Apollonia Caloro ◽

Luigi Laino ◽

Mario Alovisi ◽

Diego Sovereto ◽

...

Keyword(s):

Cell Lines ◽

Carcinoma Cell ◽

Meta Analysis ◽

Scorpion Venom ◽

In Vitro Studies ◽

Active Components ◽

Eligibility Criteria ◽

Carcinoma Cell Lines ◽

Anti Cancer

The Rhopalurus junceus is a scorpion belonging to the Buthidae family that finds its habitat in Cuba. This scorpion is known by the common name of “Blue Scorpion”. The venom is used on the island of Cuba as an alternative cure for cancer and, more recently, in the research of active components for biomedicine. Recently, the venom has been tested in several studies to investigate its effects on cancer cell lines, and the initial results of in vitro studies demonstrated how this poison can be effective on certain carcinoma cell lines (Hela, SiHa, Hep-2, NCI-H292, A549, MDA-MB-231, MDA-MB-468, and HT-29). The aim of this review is, therefore, to describe the effects of the venom on carcinoma lines and to investigate all anti-cancer properties studied in the literature. The research was conducted using four databases, Pub Med, Scopus, EBSCO, and Web of Science, through the use of keywords, by two independent reviewers following the PRISMA protocol, identifying 57 records. The results led to a total of 13 articles that met the eligibility criteria. The data extracted for the purpose of meta-analysis included the IC50 of the venom on carcinoma cell lines. The results of the meta-analysis provided a pooled mean of the IC50 of 0.645 mg/mL (95% CI: 0.557, 0.733), with a standard error (SE) = 0.045, p < 0.001. The analysis of the subgroups, differentiated by the type of cell line used, provided insight regarding how the scorpion venom was effective on the cell lines of lung origin (NCI-H292, A549, and MRC-5) with a pooled mean of IC50 0.460 mg/mL (95% CI: 0.290, 0.631) SE (0.087) p < 0.001. The results described in the literature for in vitro studies are encouraging, and further investigations should be carried out and deepened.

Download Full-text

Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy

Molecules ◽

10.3390/molecules24020266 ◽

2019 ◽

Vol 24 (2) ◽

pp. 266 ◽

Cited By ~ 6

Author(s):

Adam Bohr ◽

Thais Nascimento ◽

Necati Harmankaya ◽

Johan Weisser ◽

Yingya Wang ◽

...

Keyword(s):

Efflux Pump ◽

Water Soluble ◽

Oral Dosage ◽

In Vitro Dissolution ◽

Molar Ratio ◽

Cancer Drugs ◽

Efflux Pump Inhibitor ◽

Anti Cancer ◽

Amorphous Formulation

Many anti-cancer drugs are difficult to formulate into an oral dosage form because they are both poorly water-soluble and show poor permeability, the latter often as a result of being an intestinal efflux pump substrate. To obtain a more water-soluble formulation, one can take advantage of the higher solubility of the amorphous form of a given drug, whereas to increase permeability, one can make use of an efflux pump inhibitor. In this study, a combination of these two strategies was investigated using the co-amorphous approach, forming an amorphous mixture of two anti-cancer drugs, docetaxel (DTX) and bicalutamide (BIC). The efflux substrate, DTX, was combined with the efflux inhibitor, BIC, and prepared as a single phase co-amorphous mixture at a 1:1 molar ratio using vibrational ball milling. The co-amorphous formulation was tested in vitro and in vivo for its dissolution kinetics, supersaturation properties and pharmacokinetics in rats. The co-amorphous formulation showed a faster in vitro dissolution of both drugs compared to the control groups, but only DTX showed supersaturation (1.9 fold) compared to its equilibrium solubility. The findings for the co-amorphous formulation were in agreement with the pharmacokinetics data, showing a quicker onset in plasma concentration as well as a higher bioavailability for both DTX (15-fold) and BIC (3-fold) compared to the crystalline drugs alone. Furthermore, the co-amorphous formulation remained physically stable over 1.5 years at 4 °C under dry conditions.

Download Full-text

Potentiation of the Anti-Proliferative Effects of Anti-Cancer Drugs by Octreotide in vitro and in vivo

Digestion ◽

10.1159/000201388 ◽

1996 ◽

Vol 57 (1) ◽

pp. 22-28 ◽

Cited By ~ 22

Author(s):

G. Weckbecker ◽

F. Raulf ◽

L. Tolcsvai ◽

C. Bruns

Keyword(s):

Cancer Drugs ◽

Anti Cancer

Download Full-text